(TheNewswire)
VANCOUVER – TheNewswire- May 22, 2024 – Aequus Pharmaceuticals Inc.(TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), aspecialty pharmaceutical company focused on bringing healthcaresolutions to Canadians through licensing and partnerships, andAdvanced Ophthalmic Innovations (“AOI”), a research anddevelopment company for innovative ophthalmic implants, today announcethe signing of an exclusive distribution agreement for the PAUL®glaucoma drainage device in Canada.
“The PAUL® device is approved in over 40 countriesand used by some of the leading Ophthalmologists around the world –we are excited to bring it to Canada and provide Canadians a new andinnovative treatment option for glaucoma. We look forward to workingclosely with the AOI team to launch the PAUL® device in Canadaas early as Q4 this year ” said Grant Larsen,CCO of Aequus.
“ZIMED® PF sales are continuing to accelerate, andthe PAUL® device will further expand our value-added productportfolio in the glaucoma market. This is a synergistic addition toour existing sales infrastructure and further demonstrates ourcommitment to the improvement of eyecare in Canada” said DougJanzen, CEO and Chairman of Aequus.
Under the terms of the agreement, AOI will supply thePAUL® device and gain market authorization, and Aequus will beresponsible for the marketing, distribution, sales, and supportingongoing regulatory and market access activities.
ABOUT THE PAUL® GLAUCOMA IMPLANT:
Already available in over 40 countries around theworld, PAUL® is a glaucoma drainage device designed to regulateintraocular pressure in the patient’s eyes and prevent furtherprogression of the disease. PAUL® has introduced many innovativedesign features and unified these into one device and offers aninnovative solution for patients with moderate to severeglaucoma.
ABOUT ADVANCED OPHTHALMIC INNOVATIONS (AOI):
AOI is a research and development company based inSingapore and focuses on creating and manufacturing innovativeophthalmic implants. AOI is committed to bringing long-termvision-protecting solutions to glaucoma patients worldwide. For moreinformation about AOI, please visit: https://aoi.sg/
ABOUT AEQUUS PHARMACEUTICALS INC.
Aequus Pharmaceuticals Inc. (TSX-V: AQS , OTCQB: AQSZF ) isspecialty pharmaceutical company focused on developing andcommercializing high quality, differentiated products inophthalmology. Aequus plans to build on its Canadian commercialplatform through the launch of additional products that are eithercreated internally or brought in through an acquisition or license;remaining focused on highly specialized therapeutic areas. For furtherinformation, please visit www.aequuspharma.ca .
FORWARD-LOOKINGSTATEMENT DISCLAIMER
This release may contain forward-looking statementswithin the meaning of the U.S. Private Securities Litigation ReformAct of 1995 or forward-looking information under applicable Canadiansecurities legislation (collectively, “forward-lookingstatements”) that may not be based on historical fact, including,without limitation, statements containing the words “believe”,“may”, “plan”, “will”, “estimate”, “continue”,“anticipate”, “intend”, “expect”,“potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptionsmade by us in light of our experience and perception of historicaltrends, current conditions and expected future developments, as wellas the factors we believe are appropriate. Forward-looking statementsinclude but are not limited to statements relating to: the launch ofthe PAUL® device in Canada as early as Q4 this year, the accelerationof ZIMED® PF sales, the expectation that the PAUL® device willfurther expand our value-added product portfolio in the glaucomamarket and matters related to the future performance of the exclusivedistribution agreement. Such statements reflect our current views withrespect to future events and are subject to risks and uncertaintiesand are necessarily based upon a number of estimates and assumptionsthat, while considered reasonable by Aequus, are inherently subject tosignificant business, economic, competitive, political and socialuncertainties and contingencies. Many factors, including the riskfactors noted below, could cause our actual results, performance, orachievements to be materially different from any future results,performance, or achievements that may be expressed or implied by suchforward-looking statements. In making the forward looking statementsincluded in this release, the Company has made various materialassumptions, including, but not limited to: obtaining regulatoryapprovals; general business and economic conditions; the Company’sability to successfully out license or sell its current products andinlicense and develop new products; the assumption that theCompany’s current good relationships with third parties will bemaintained; the availability of financing on reasonable terms; theCompany’s ability to attract and retain skilled staff; marketcompetition; the products and technology offered by the Company’scompetitors; the impact of the coronavirus (COVID-19) on theCompany’s operations; and the Company’s ability to protect patentsand proprietary rights. In evaluating forward looking statements,current and prospective shareholders should specifically considervarious factors set out herein and under the heading “RiskFactors” in the Company’s Annual Information Form dated May 1,2023, a copy of which is available on Aequus’ profile on the SEDAR+website at www sedarplus.ca, and as otherwise disclosed from time totime on Aequus’ SEDAR+ profile. Should one or more of these risks oruncertainties, or a risk that is not currently known to usmaterialize, or should assumptions underlying those forward-lookingstatements prove incorrect, actual results may vary materially fromthose described herein. These forward-looking statements are made asof the date of this release and we do not intend, and do not assumeany obligation, to update these forward-looking statements, except asrequired by applicable securities laws. Investors are cautioned thatforward-looking statements are not guarantees of future performanceand are inherently uncertain. Accordingly, investors are cautioned notto put undue reliance on forward looking statements.
Neither TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this release.
CONTACT INFORMATION
Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906
Copyright (c) 2024 TheNewswire - All rights reserved.